Molekulargenetisches Labor
Zentrum für Nephrologie und Stoffwechsel
Moldiag Erkrankungen Gene Support Kontakt

Tyrosine-Proteinkinase JAK2

Das JAK2-Gen kodiert eine Tyrosine-Proteinkinase, die in der Signalkaskade verschiedener Zytokine eingebunden ist. Keimbahnmutationen führen zu Thrombozytämie 3 und somatische Mutationen zu verschiedenen anderen Bluterkrankungen und dem Budd-Chiari-Syndrom.

Gentests:

Klinisch Untersuchungsmethoden Familienuntersuchung
Bearbeitungszeit 5 Tage
Probentyp genomische DNS
Klinisch Untersuchungsmethoden Hochdurchsatz-Sequenzierung
Bearbeitungszeit 25 Tage
Probentyp genomische DNS
Forschung Untersuchungsmethoden Direkte Sequenzierung der proteinkodierenden Bereiche eines Gens
Bearbeitungszeit 25 Tage
Probentyp genomische DNS
Klinisch Untersuchungsmethoden Multiplex ligationsabhängige Amplifikation
Bearbeitungszeit 25 Tage
Probentyp genomische DNS

Verknüpfte Erkrankungen:

Somatische Erythrozytose
JAK2
Akute myeloische Leukämie
JAK2
Osteomyelofibrose
JAK2
Polycythaemia vera
JAK2
Thrombozythämie 3
JAK2
Budd-Chiari-Syndrom
JAK2

Referenzen:

1.

Scott LM et al. (2007) JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.

external link
2.

Saltzman A et al. (1998) Cloning and characterization of human Jak-2 kinase: high mRNA expression in immune cells and muscle tissue.

external link
3.

Schwaller J et al. (2000) Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2.

external link
4.

Digicaylioglu M et al. (2001) Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades.

external link
5.

Huang LJ et al. (2001) The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor.

external link
6.

Tefferi A et al. (2005) JAK2 mutations in myeloproliferative disorders.

external link
7.

Campbell PJ et al. (2005) Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.

external link
8.

Jamieson CH et al. (2006) The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation.

external link
9.

Patel RK et al. (2006) Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome.

external link
10.

Sozer S et al. (2009) The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome.

external link
11.

Mercier E et al. (2007) JAK2 V617F mutation in unexplained loss of first pregnancy.

external link
12.

Bercovich D et al. (2008) Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome.

external link
13.

Dahabreh IJ et al. (2009) No evidence for increased prevalence of JAK2 V617F in women with a history of recurrent miscarriage.

external link
14.

Jones AV et al. (2009) JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms.

external link
15.

Kilpivaara O et al. (2009) A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms.

external link
16.

Olcaydu D et al. (2009) A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms.

external link
17.

Dawson MA et al. (2009) JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin.

external link
18.

Mullighan CG et al. (2009) Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia.

external link
19.

Parganas E et al. (1998) Jak2 is essential for signaling through a variety of cytokine receptors.

external link
20.

Chung RT et al. (2006) Case records of the Massachusetts General Hospital. Case 15-2006. A 46-year-old woman with sudden onset of abdominal distention.

external link
21.

Lee JW et al. (2006) The JAK2 V617F mutation in de novo acute myelogenous leukemias.

external link
22.

Ortmann CA et al. (2015) Effect of mutation order on myeloproliferative neoplasms.

external link
23.

Baxter EJ et al. () Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.

external link
24.

Kralovics R et al. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders.

external link
25.

Méndez-Ferrer S et al. (2008) Haematopoietic stem cell release is regulated by circadian oscillations.

external link
26.

Méndez-Ferrer S et al. (2010) Mesenchymal and haematopoietic stem cells form a unique bone marrow niche.

external link
27.

Arranz L et al. (2014) Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms.

external link
28.

James C et al. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.

external link
29.

Mead AJ et al. (2012) Germline JAK2 mutation in a family with hereditary thrombocytosis.

external link
30.

Pritchard MA et al. (1992) Two members of the JAK family of protein tyrosine kinases map to chromosomes 1p31.3 and 9p24.

external link
31.

Campbell GS et al. (1994) Activation of JAK2 tyrosine kinase by prolactin receptors in Nb2 cells and mouse mammary gland explants.

external link
32.

Gough NM et al. (1995) Localization of genes for two members of the JAK family of protein tyrosine kinases to murine chromosomes 4 and 19.

external link
33.

Watling D et al. (1993) Complementation by the protein tyrosine kinase JAK2 of a mutant cell line defective in the interferon-gamma signal transduction pathway.

external link
34.

Peeters P et al. (1997) Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia.

external link
35.

Lacronique V et al. (1997) A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia.

external link
36.

Neubauer H et al. (1998) Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis.

external link
37.

NCBI article

NCBI 3717 external link
38.

OMIM.ORG article

Omim 147796 external link
39.

Orphanet article

Orphanet ID 122727 external link
Update: 14. August 2020
Copyright © 2005-2020 Zentrum für Nephrologie und Stoffwechsel, Dr. Mato Nagel
Albert-Schweitzer-Ring 32, D-02943 Weißwasser, Deutschland, Tel.: +49-3576-287922, Fax: +49-3576-287944
Seitenüberblick | Webmail | Haftungsausschluss | Datenschutz